Vivus, Inc.

Alza Corporation

Other

Asivi, LLC

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Department of Health

Pavex, Inc.

Virgil A. Place

Robert M. Gale

Randall G. Berggren

Virgil A Place

Paul C Doherty, Jr

Mark S Hanamoto

Patrick S Wong

Leland F Wilson

William L Smith

Brian L Barclay

Jerry D Childers

Neil Gesundheit

Sean R Bennett

Alfred P Spivack

Jeri D Wright

Robert M Gale

Randall G Berggren

James B Eckenhoff

John R Peery

Larry K Keefer

Patricia S Campbell

Joseph E Saavedra

Juan M Harrison

Myriam T Encarnacion

Martin S Gerstel

Harold L Crow

Ibrahim AbouBakr Abdel-Hamid Abdou Ali

Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.

Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists

Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.

Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction

A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.

Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction

Methods and formulations for minimizing excess collagen are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others.

Method for minimizing excess collagen deposition

Treatment of female sexual dysfunction using phosphodiesterase inhibitors

A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as &ldquo;as needed&rdquo; basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.

Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation

Treatment of female sexual dysfunction

A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided is a nitric oxide delivery means for use in the method.

Use of nitric oxide-releasing agents to treat impotency

A buccal dosage unit is provided for administering a combination of steroidal active agents to a female individual. The novel buccal drug delivery systems may be used in female hormone replacement therapy, in female contraception, to treat female sexual dysfunction, and to treat or prevent a variety of conditions and disorders which are responsive to the active agents discussed herein. The buccal dosage unit comprises a progestin, an estrogen and optionally an androgenic agent, as well as a polymeric carrier that bioerodes and provides for delivery of the active agents throughout a predetermined drug delivery period.

Buccal drug administration in the treatment of female sexual dysfunction

A simple and compact buccal dosage unit is provided for administering a pharmacologically active agent to a mammalian individual. The buccal dosage unit comprises the active agent to be administered, a polymeric carrier that bioerodes and provides for delivery of the androgenic agent over a predetermined time period, and, preferably, a lubricant such as magnesium stearate. The dosage units are ideal for administering drugs that have low oral bioavailability but are nevertheless potent and can thus be administered in small quantities, i.e., at low dosages, using the compact systems. Methods for administering active agents using the dosage units are provided as well.

Compact dosage unit for buccal administration of a pharmacologically active agent

Method for facilitating transmucosal delivery of steroidal active agents

A method is provided for delaying the onset of ejaculation in an individual. The method preferably involves administration of an antidepressant drug, a serotonin agonist or antagonist, an adrenergic agonist or antagonist, an adrenergic neurone blocker, or a derivative analog thereof, within the context of an effective dosing regimen. The preferred mode of administration is transurethral; however, the selected active agent may also be delivered via intracavernosal injection or using alternative routes. Pharmaceutical formulations and kits are provided as well.

Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation

Buccal drug administration in female hormone replacement therapy

Contraceptive method employing buccal delivery of steroidal active agents

Growing community of inventors

Kawaihae, HI, United States of America

Virgil A Place